[Federal Register: April 29, 2009 (Volume 74, Number 81)]
[Notices]
[Page 19570-19571]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29ap09-92]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number 105-A]
Updating the List of Hazardous Drugs for the NIOSH Alert:
Additions and Deletions to the NIOSH Hazardous Drug List
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of draft document available for public comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
announces the availability of the following draft document available
for public comment entitled ``Updating the List of Hazardous Drugs for
the NIOSH Alert: Additions and Deletions to the NIOSH Hazardous Drug
List.'' The document and instructions for submitting comments can be
found at http://www.cdc.gov/niosh/review/public/105a/.
DATES: Comments must be postmarked by June 30, 2009.
ADDRESSES: You may submit comments to nioshdocket@cdc.gov or to the
NIOSH Docket Office, Robert A. Taft Laboratories, MS-C34, 4676 Columbia
Parkway, Cincinnati, OH 45226 or by facsimile (513) 533-8285. Comments
should be in Microsoft Word format and should reference NIOSH docket
number 105-A. NIOSH includes all comments received without change in
the docket, including any personal information provided. After the
comment period has closed, comments will be able to be accessed
electronically at http://www.cdc.gov/NIOSH under the link to the NIOSH
docket. As appropriate, NIOSH will post comments with the commenters'
names, affiliations and other information, on the Internet.
Background: The ``NIOSH Alert: Preventing Occupational Exposures to
Antineoplastic and Other Hazardous Drugs in Health Care Settings'' was
published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/).
Since that time, approximately 60 new drugs have received FDA approval
and approximately 60 drugs have received special warnings (usually
black box warnings) based on reported adverse effects in patients. An
additional 18 drugs were included from the updated National Institutes
of Health (NIH) Hazardous Drug List. From this list of approximately
150 drugs, 62 drugs were determined to have one or more characteristic
of a hazardous drug and published for comment in NIOSH docket number
105.
After review by experts, public review and comment, input from
stakeholders and review of the scientific literature, NIOSH has
proposed a second draft list of hazardous drugs. A number of drugs were
removed from the initial proposed list based on comments from the
various groups and organizations. The second draft list identifies 24
drugs that fit the NIOSH definition of hazardous drugs. Based on
comments received by NIOSH, Bacillus Calmette-Guerin (BCG) will be
removed from Appendix A in the 2004
[[Page 19571]]
NIOSH Alert on Hazardous Drugs (http:// www.cdc.gov/niosh/docs/2004-
165/) due to potential adverse effects in some patients from cross-
contamination.
This guidance document does not have the force and effect of law.
FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A.
Taft Laboratories, MS-C26, 4676 Columbia Parkway, Cincinnati, OH 45226,
telephone (513) 533-8132, E-mail: hazardousdrugs@cdc.gov.
Reference: http://www.cdc.gov/niosh/docs/2004-102/. Web address for
this document: http://www.cdc.gov/niosh/review/public/105a/. All
information received in response to this notice will be available for
public examination and copying at the NIOSH Docket Office, 4676
Columbia Parkway, Room 111, Cincinnati, Ohio, 45226, telephone (513)
533-8303.
Dated: April 22, 2009.
Christine M. Branche,
Acting Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. E9-9779 Filed 4-28-09; 8:45 am]
BILLING CODE 4163-19-P